Strumento inattivo

Altre lingue Summit Therapeutics plc London S.E.

Azioni

GB00BN40HZ01

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer	24/06
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Chief Financial Officer	24/06
Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP	18/06
Summit Therapeutics Inc. Announces Resignation of Ujwala Mahatme as Member of its Board	13/06
Sector Update: Health Care Stocks Steady Premarket Monday	03/06
Summit Therapeutics Generates $200 Million Through Share Sale; Expand License Territories for Ivonescimab	03/06
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab	03/06
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	03/06
Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP	03/06
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA	01/06
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy	01/06
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	31/05
Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations	31/05
Sector Update: Health Care	31/05
US Futures Trend Modestly Lower Pre-Bell Friday as Investors Await Key Inflation Report	31/05
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	31/05
Health Care Stocks Steady -- Health Care Roundup	30/05
Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival	30/05
US Equities Markets Close Lower Thursday After Q1 Economic Growth Found to be Slower Than Projected	30/05
Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar	30/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Summit Therapeutics plc London S.E.

Azioni

GB00BN40HZ01

Altre lingue

Filtri